Fachbereich Veterinärmedizin


Service-Navigation

    Publikationsdatenbank

    Towards an inhalative in vivo application of immunomodulating gelatin nanoparticles in horse-related preformulation studies (2012)

    Art
    Zeitschriftenartikel / wissenschaftlicher Beitrag
    Autoren
    Fuchs, Sebastian
    Klier, John
    May, Anna
    Winter, Gerhard
    Coester, Conrad
    Gehlen, Heidrun
    Quelle
    Journal of microencapsulation : microcapsules, liposomes, nanocapsules, microcells; 29(7) — S. 615–625
    ISSN: 0265-2048
    Sprache
    Englisch
    Verweise
    DOI: 10.3109/02652048.2012.668962
    Pubmed: 22432849
    Kontakt
    Klinik für Pferde, allgemeine Chirurgie und Radiologie

    Oertzenweg 19 b
    14163 Berlin
    Tel.+49 30 838 62299 Fax.+49 30 838 62529
    email:pferdeklinik@vetmed.fu-berlin.de

    Abstract / Zusammenfassung

    Delivering active ingredients using biocompatible and biodegradable carriers such as gelatin nanoparticles (GNPs) to the lung constitutes a promising non-invasive route of administration. However, the pulmonary delivery of nanoparticle-based immunotherapy is still a field that requires more clarification. In this study, GNPs loaded with cytosine-phosphate-guanine oligodeoxynucleotides (CpG-ODN)-loaded and plain GNPs were aerosolised either by a conventional pressured metered dose inhaler (pMDI) or by active or passive vibrating-mesh (VM) nebulisers. GNP sizes after nebulisation by active and passive VM nebulisers were 248.2 ± 7.34 and 222.3 ± 1.42 nm, respectively. GNP concentrations after aerosolisation were found consistent and second-stage particle deposition in an impinger was up to 65.68 ± 11.2% of the nebulised dose. VM nebulisers produced high fine particle fractions, while pMDIs did not. Nebulised CpG-ODN-loaded GNPs remained capable to stimulate IL-10 release (225.2 ± 56.3 pg/ml) in vitro from equine alveolar lymphocytes. Thus, a novel system for pulmonary GNP-mediated immunotherapy in vivo was established.